Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the United Kingdom

Clinical Infectious Diseases

Volumn 61, Issue 5, 2015, Pages 829-836

  Mbisa, Jean L ^a   Fearnhill, Esther ^b   Dunn, David T ^b   Pillay, Deenan ^c   Asboe, David ^d   Cane, Patricia A ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

HIV 1 transmitted drug resistance; Subtype B; Treatment naive patients

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BASIC REPRODUCTION NUMBER; COMPARATIVE STUDY; FEMALE; GENE MUTATION; GENETIC DISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; STRUCTURAL GENE; TRANSMITTED DRUG RESISTANCE; UNITED KINGDOM; ANTIVIRAL RESISTANCE; CLASSIFICATION; GENETICS; HIV INFECTIONS; STATISTICAL MODEL; VIROLOGY;

DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MODELS, STATISTICAL; PHYLOGENY; UNITED KINGDOM;

EID: 84942026386     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ393     Document Type: Article

References (24)

1. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (updated November 2013. All changed text is cast in yellow highlight.). HIV Med 2014; 15(suppl 1):1-85.
2. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
3. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
4. Dolling D, Sabin C, Delpech V, et al. Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ 2012; 345:e5253.
5. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11:363-71.
6. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37:1570-3.
7. Castro H, Pillay D, Cane P, et al. Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis 2013; 208:1459-63.
8. Yerly S, Rakik A, De Loes SK, et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998; 72:3520-3.
9. Dolling D, Nelson M, Schwenk A, et al. Rapid increase in the frequency of wildtypeHIV-1drugresistancereportsamongART-experiencedpatients: UK [abstract 594]. In: Programs and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections (Atlanta). Alexandria, VA: Conference on Retroviruses and Opportunistic Infections, 2013:319.
10. Yerly S, Jost S, Telenti A, et al. Infrequent transmission of HIV-1 drugresistant variants. Antivir Ther 2004; 9:375-84.
11. Taylor S, Cane P, Hue S, et al. Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations. AIDS Res Hum Retroviruses 2003; 19:353-61.
12. Hue S, Gifford RJ, Dunn D, Fernhill E, Pillay D. Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 2009; 83:2645-54.
13. Drescher SM, von Wyl V, Yang WL, et al. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis 2014; 58:285-94.
14. Pillay D, Green H, Matthias R, et al. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 2005; 192:967-73.
15. Alcantara LC, Cassol S, Libin P, et al. A standardized framework for accurate, high-throughput genotyping of recombinant and nonrecombinant viral sequences. Nucleic Acids Res 2009; 37(Web Server issue):W634-42.
16. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-800.
17. Price MN, Dehal PS, Arkin AP. FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol 2009; 26:1641-50.
18. Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 2007; 7:214.
19. Stadler T, Kouyos R, von Wyl V, et al. Estimating the basic reproductive number from viral sequence data. Mol Biol Evol 2012; 29:347-57.
20. Phillips AN, Cambiano V, Nakagawa F, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One 2013; 8:e55312.
21. Frost SD, Volz EM. Viral phylodynamics and the search for an 'effective number of infections'. Philos Trans R Soc Lond B Biol Sci 2010; 365:1879-90.
22. Volz EM, Kosakovsky Pond SL, Ward MJ, Leigh Brown AJ, Frost SD. Phylodynamics of infectious disease epidemics. Genetics 2009; 183: 1421-30.
23. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. The epidemic behavior of the hepatitis C virus. Science 2001; 292:2323-5.
24. Leventhal GE, Gunthard HF, Bonhoeffer S, Stadler T. Using an epidemiological model for phylogenetic inference reveals density dependence in HIV transmission. Mol Biol Evol 2014; 31:6-17.